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PPAR involvement in cell growth was investigated “in vivo” and “in vitro” and was correlated with cell proliferation and apoptotic
death. “In vivo” PPARγ and α were evaluated in colon cancer specimens and adjacent nonneoplastic colonic mucosa. PPARγ
increased in most cancer specimens versus mucosa, with a decrease in c-Myc and in PCNA proteins, suggesting that colon cancer
growth is due to increased cell survival rather than increased proliferation. The prevalence of survival over proliferation was
conﬁrmed by Bcl-2 or Bcl-XL increase in cancer versus mucosa, and by decreased PPARα.“ I nv i t r o ”P P A R γ and PPARα were
evaluated in human tumor and normal cell lines, treated with natural or synthetic ligands. PPARγ was involved in inhibiting cell
proliferation with a decrease in c-Myc protein, whereas PPARα was involved in inducing apoptosis with modulation of Bcl-2 and
Bad proteins. This involvement was conﬁrmed using speciﬁc antagonists of two PPARs. Moreover, the results obtained on treating
cell lines with PPAR ligands conﬁrm observations in colon cancer: there is an inverse correlation between PPARα and Bcl-2 and
between PPARγ and c-Myc.
Copyright © 2007 G. Martinasso et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1. INTRODUCTION
Nuclear receptors are attractive targets for novel therapeutic
approaches to cancer. Treating malignant tumors by induc-
ing cell diﬀerentiation is an attractive concept, but the clin-
ical development of diﬀerentiation-inducing agents to treat
malignant tumors, especially for solid tumors, has been lim-
ited to date [1].
Among the large group of nuclear receptors, a special
placeisoccupiedbyperoxisomeproliferator-activatedrecep-
tors (PPARs), which are involved in controlling metabolism,
growth,andimmuneandinﬂammatoryresponses[2].Inad-
dition to these metabolic and anti-inﬂammatory properties,
PPARs have been indicated as both tumor suppressors and
tumorpromoters[3,4].Uponactivationbyspeciﬁcagonists,
these receptors form dimers with RXR receptors and translo-
cate to the nucleus, where they act as agonist-dependent
transcription factors and regulate gene expression by bind-
ing to speciﬁc promoter regions of target genes [5, 6].
PPARγ is expressed in many cancers, including colon,
breast,andprostate,andspeciﬁcPPARγ agonists,suchasthi-
azolidinediones, are generally considered antiproliferative in
these settings [7]. However, although PPARγ acts as a tumor
suppressor in colon cancer, colon tumors with mutations in
the APC gene appear to be exceptions, since thiazolidine-
diones promote growth in these tumors [8, 9].
Less is known about the role of PPARα in human tu-
mors. Generally, activation of this PPAR by exogenous ago-
nists causes inhibition of tumor cell growth [10–12]. Among
speciﬁc agonists of PPARα,ﬁ b r a t e s ,aw i d e l yu s e dc l a s so f
hypolipidemic drugs, act by modulating transcription of
genes encoding proteins that control lipid transport and
metabolism, andalsoexertpleiotropic anti-inﬂammatoryef-
fects by downregulating the expression of genes encoding
inﬂammatory cytokines and acute-phase response proteins
[13]. These combined actions translate into clinical beneﬁts,
as demonstrated by reduced cardiovascular morbidity and
mortality in primary and secondary intervention trials [14].
The physiological and pharmacological roles of PPARβ
(also referred to as PPARδ) are just beginning to emerge.
It has recently become clear that PPARβ has a function in
epithelial tissues, but inconsistent reports leave the situa-
tion controversial. There is strong evidence that activation
of PPARβ by ligands such as di(2-ethylhexyl) phthalate can2 PPAR Research
induce terminal diﬀerentiation of keratinocytes, with con-
comitant inhibition of cell proliferation [15, 16]. However,
the role of PPARβ in keratinocyte-speciﬁc apoptosis is less
clear, and its role in colonic epithelium is also unclear due to
conﬂicting evidence suggesting that its ligand activation can
both potentiate and attenuate intestinal cancer [16].
PPAR isoforms are receptors for several ligands, some of
which are natural, such as PUFAs and their derivatives, while
others are synthetic, such as the above-mentioned ﬁbrates
and phthalates. The ligands have diﬀerent aﬃnities for the
receptors. All three isoforms can be activated by n-3 and n-
6 PUFAs, although the aﬃnity of PUFAs for the receptors
varies, which suggests a role for site-speciﬁc availability and
metabolism of particular fatty acids and diﬀerences in their
aﬃnities for speciﬁc PPAR subtypes [17].
Our interest is to demonstrate the diﬀerent involvements
of PPARs in cell growth, with particular attention to the car-
cinogenic process, and to correlate them to cell proliferation
and death by apoptosis. Investigations have been carried out
both “in vivo” and “in vitro.” “In vivo” PPAR protein con-
tent was evaluated in several colon cancer specimens from
patients undergoing surgery to remove tumors. “In vitro”
PPAR protein content was evaluated in the human lung-
tumor A549 cell line and in the normal human proliferat-
ing NCTC 2544 cell line. These two cell lines were chosen
because the ﬁrst does not express PPARα, whereas the sec-
ond does not express PPARγ.T h e yt h u sa p p e a r e dt ob ea
good choice to show the importance of PPARγ and PPARα
in cell proliferation and apoptosis. To induce PPARs, docosa-
hexaenoic acid (DHA) was chosen as ligand for PPARγ and
cloﬁbrate for PPARα.
2. MATERIALS AND METHODS
2.1. Colontissuesamples
Specimens of colon cancer and adjacent nonneoplastic
colonic mucosa were obtained from surgically excised mate-
rial of 24 patients at the Oncological Center, Molinette Hos-
pital, Turin, Italy. Adjacent connective tissue was in all cases
stripped to eliminate fat contamination, and colonic cancer
specimens were without nonneoplastic colon mucosa; speci-
mens were immediately frozen and stored at −80◦C.
2.2. Cultureconditions
A549 human lung adenocarcinoma cells (ATCC, USA) were
seeded (25000cells/cm2) and maintained for 24 hours in
Ham’s F-12K medium supplemented with 2mM glutamine,
1% (v/v) antibiotic/antimycotic solution (medium A), and
10% (v/v) fetal bovine serum (FBS). Human keratinocyte
NCTC 2544 cells (kind gift from Dr.Bassi, University of
Genoa, Italy) were seeded (20000cells/cm2) in DMEM (low
glucose medium) plus 2mM glutamine, 1% (v/v) antibi-
otic/antimycotic solution, 1% nonessential amino acids, and
10% (v/v) fetal bovine serum. All cells were maintained at
37◦C in a humidiﬁed atmosphere of 5% CO2 in air.
2.3. TreatmentofA549cellswith
docosahexaenoicacid
A stock solution of free fatty acid (100mM in FBS) was pre-
pared and stored at −20◦C until use. Fatty acid was pur-
chased from Sigma Chemical Co. (St. Louis, Mo).
Twenty four hours after cell seeding (time 0), culture
medium was removed and replaced by medium B (medium
A plus 0.4% serum bovine albumin (fatty-acid free), 1% ITS
(insulin, transferrin, sodium selenite), 1% vitamin solution)
supplemented or not with DHA. Stock solution of DHA was
diluted to the ﬁnal concentrations, reported in the ﬁgures,
directly in medium B, used to replace medium A. FBS was
added to control cells.
Forty eight hours after DHA addition, treated and con-
trol cells were trypsinized after collecting culture media, har-
vested and centrifuged at 600g for 10minutes to carry out
the assays listed below.
2.4. TreatmentofA549cellswithdocosahexaenoic
acidandPPARγ antagonist
Twenty four hours after cell seeding (time 0), culture medi-
um was removed and replaced by medium B supplemented
with 50μM DHA and 10μM GW9662. The cells were pro-
cessed as explained above.
2.5. TreatmentofNCTC2544withcloﬁbrate
Twenty four hours after cell seeding, cloﬁbrate dissolved in
DMSO (maximum ﬁnal concentration 0.05%) was added to
cells at the concentrations reported in the ﬁgures. Solvent
alonewasaddedtocontrolcells.At24-or48-hourtreatment,
the cells were trypsinized after collecting culture media, and
centrifuged at 600g for 10minutes. Cells and culture media
were used for the assays listed below.
2.6. TreatmentofNCTC2544withcloﬁbrateand
PPARαantagonist
Twenty four hours after cell seeding, 250μM cloﬁbrate and
5μM MK886 were added to cells. The cells were processed as
explained above.
2.7. Cellproliferation
Cell proliferation was determined as by Martinasso et al.
[15].
2.8. Apoptosis
Apoptosis was determined by evaluating the presence of a
sub-G0/G1 peakinﬂow cytometricanalysisasbyMartinasso
etal.[15],andbyTUNELstaining. Forﬂowcytometricanal-
ysis, brieﬂy, cells were washed in PBS, ﬁxed in ice-cold 70%
ethanol for at least 30minutes, incubated at room temper-
ature in PBS containing DNase-free RNase (type II-A) and
propidium iodide, respectively, at ﬁnal concentrations of 0.4G. Martinasso et al. 3
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Figure 1: PPARγ, c-Myc, PCNA, PPARα, Bcl-2, and Bcl-XL protein contents in colon cancer specimens.Values are means ± SD of 19
patients for PPARγ, 20 patients for PCNA and c-Myc (a), 21 patients for PPARα, 13 patients for Bcl-2, and 18 patients for Bcl-XL (b). The
densitometry value of each protein for each patient was normalized to the corresponding β-actin value and was expressed as related to that
of the corresponding mucosa specimen, set arbitrarily to 1. ∗ t test, colon cancer versus nonneoplastic mucosa (P<. 05).
and 0.18mg/mL, and then analyzed with a FACScan ﬂow cy-
tometer (Becton & Dickinson, Mountain View, Calif, USA)
equipped with a 488nm argon laser and 2 ﬁlters, transmit-
ting at 585nm (FL2) and above 620nm (FL3), respectively.
Data were recorded on a Hewlett Packard computer (HP
9000, model 300), using CellFit software (Becton & Dickin-
son).
TUNEL staining was performed using the DeadEnd Col-
orimetric TUNEL System (Promega, Madison, Wis, USA)
following the manufacturer’s instructions.
2.9. Westernblotanalysis
For each specimen, about 50mg of tissue were washed
twice in cold PBS and then homogenized by sonication
in 150μLo fl y s i sb u ﬀer (Totex buﬀer (pH 7.9) containing
20mM Hepes, 350mM NaCl, 20% glycerol, 1% NP-40 sub-
stitute, 1mM MgCl2,0 . 5m ME D T A ,0 . 1m ME G T A ,1m M
Na-orthovanadate, 1mM phenyl methyl sulfonyl ﬂuoride,
15μg/mLleupeptin).Thehomogenateswerekeptonicefor1
hour and then centrifuged in a microfuge at 13500rpm, for
25minutes. Collected cells were washed twice in cold PBS,
suspended to 50% (w/v) in the same lysis buﬀer, incubated
in ice for 30minutes, and sonicated. The homogenates were
centrifuged in a microfuge at 12000rpm, for 10minutes.
The supernatants containing the extracted proteins were
then collected and used for Western blot analysis.
After SDS-polyacrylamide gel electrophoresis, the pro-
teins were electrotransferred to a PVDF membrane, which
was then blocked overnight with TBS containing 10% non-
fat dried milk. The membranes were then rinsed and incu-
batedwithpolyclonalanti-PPARγ,anti-PPARα,anti-PPARβ,
anti-PCNA (proliferating cell nuclear antigen), anti-Bcl-2,
or anti-Bcl-XL antibodies, with monoclonal anti-Bad, anti-
c-Myc (all from Santa Cruz Biotechnology, Germany), or
anti-β-actin antibodies (from Sigma Chemical Co., St. Louis,
Mo, USA). Protein bands were visualized using a chemilumi-
nescent detection system (Immun-Star HRP, Bio-Rad, Calif,
USA).
2.10. Proteindetermination
Protein content was determined with the Protein Assay Kit 2
(Bio-Rad).
2.11. Statisticalanalysis
A lld a t aa r ee x p r e s s eda sm e a n s± SD. The signiﬁcance of dif-
ferencesbetweengroupmeanswasassessedbyvarianceanal-
ysis, followed by the Newman-Keuls test or by the student t
test.
3. RESULTS
3.1. PPARγ andPPARαproteincontentincoloncancers
“In vivo” PPARγ and PPARα proteins content was evalu-
ated in cancer specimens from patients undergoing surgery
to remove colon tumors. Samples of adjacent nonneoplastic
colonic mucosa from the same patients were also collected
for comparison. In 19 of 24 patients, PPARγ protein content
was higher in cancer specimens than in mucosa specimens,
showing that PPARγ was generally increased in cancer versus
mucosa (Figure 1(a)) .P r o t e i nc o n t e n t si ne a c hm u c o s as p e c -
imen were set arbitrarily to 1, and values relating to tumor
specimens referred to the corresponding mucosa specimen.
The PPARγ increase was coupled with a decrease in c-
Myc and in PCNA (Figure 1(a)), suggesting that colon can-
cer growth is due to increased survival rather than due to
increased cell proliferation. In 20 of 24 patients, the protein4 PPAR Research
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Figure 2: Apoptosis evaluated in mucosa and colon cancer by
TUNEL staining.
content of c-Myc and of PCNA in cancer specimens was
above that in mucosa specimens. The prevalence of cell sur-
vival over cell proliferation was conﬁrmed by the increase
of Bcl-2 or Bcl-XL, both antiapoptotic proteins, in cancer
versus mucosa specimens, and by the decrease of PPARα
(Figure 1(b)). PPARα was decreased in 21 patients, Bcl-2 was
increased in 13 patients, and Bcl-XL was increased in 18 pa-
tients of 24 patients. Only in 2 patients were both Bcl-2 and
Bcl-XL decreased. In all patients, an inverse correlation be-
tween PPARα and antiapoptotic proteins was observed. No
univocal changes were observed for PPARβ (data not re-
ported).
3.2. Apoptosisincoloncancers
Apoptosis was evaluated by TUNEL staining, as shown in
Figure 2.Innonneoplasticcolonicmucosa,alargenumberof
TUNEL-positivenucleiwereevident,whereasincancerspec-
imens the number of TUNEL-positive nuclei was lower than
in corresponding mucosa.
3.3. PPARproteincontentsinhumancelllines
“In vitro” PPARγ, β and α protein contents were evaluated
in tumor (lung adenocarcinoma A549) and normal (ker-
atinocytes NCTC 2544) human cell lines, treated with nat-
ural or synthetic ligands (DHA or cloﬁbrate). DHA was used
as ligand of PPARγ, whereas cloﬁbrate was used as speciﬁc
ligand of PPARα.
Figure 3 shows the increase of protein content of PPARγ
inversely correlated with the inhibition of cell proliferation,
as evidenced by the decrease of cell numbers and of c-Myc
in cells treated with PUFA at diﬀerent concentrations for 48
hours in comparison with control cells. The protein content
of PPARγ and c-Myc in treated cells referred to content of
control cells, set arbitrarily to 1. No cells in apoptosis or in
necrosis were found after treating A549 cells with this ligand
(data not shown). With regard to PPARβ and α protein con-
tents, in A549 cells only PPARβ w a si n c r e a s e d ,a si ti sa l s o
shown in Figure 3(b), since PPARα was not expressed (data
not shown).
PPARγ was also found to be involved in the signal trans-
duction pathway inhibiting cell proliferation, for example in
HepG2 treated with CLA and in A549 treated with arachi-
donic acid [18, 19].
PPARα has been reported to be involved in the sig-
nal transduction pathway inducing apoptosis [18, 20]. As
Figure 4 shows, PPARα protein content (Figure 4(b))w a s
increased in NCTC 2544 cells treated with cloﬁbrate, at
diﬀerent concentrations for 48 hours, in comparison with
control cells; apoptosis increased in parallel (Figure 4(a)).
PPARγ and β were also evaluated: the former was not ex-
pressed, whereas the latter (Figure 4(b)) was decreased by
treatment with cloﬁbrate.
Apoptosis was evaluated by ﬂow cytoﬂuorimetric anal-
ysis, and TUNEL staining was also carried out to con-
ﬁrm the presence of cells in apoptosis. Figure 5 shows that
NCTC 2544 cells treated with 250μM cloﬁbrate were pos-
itive to TUNEL staining, indicating DNA fragmentation
(Figure 5(b)); untreated cells (Figure 5(a))w e r ea l ln e g a t i v e
to TUNEL staining.
The increase in PPARα observed in NCTC 2544 cells
(Figure 4) was accompanied by a decrease in Bcl-2 and by
an increase in Bad (Figure 4(c)). The content of the diﬀerent
proteinsintreatedcellsreferredtothecorrespondingcontent
in control cells, set arbitrarily to 1.
TheconcentrationsofPUFAandﬁbrateswereshownnot
to be cytotoxic, by determining the activity of lactate dehy-
drogenases in the medium; no increase of enzyme release oc-
curred (data not shown).
3.4. EffectofPPARγ orPPARαantagoniston
cellproliferationorapoptosis
To demonstrate the involvement of PPARs in cell prolifera-
tionorapoptosis,aspeciﬁcantagonistforeachPPARstudied
was added to cells at the same time as the PPAR ligand.
Figure 6 shows that the PPARγ antagonist, GW9662,
completely prevented the inhibition induced by DHA on
A549 cell proliferation (Figure 6(a)), and that the PPARα an-
tagonist, MK886, almost completely prevented the induc-
tion of apoptosis induced by cloﬁbrate in NCTC 2544 cells
(Figure 6(b)).
4. DISCUSSION
PPARs are transcription factors that may be involved in the
modulation of cell proliferation and apoptosis; to strengthen
this observation, their expression was evaluated “in vivo” in
c o l o nc a n c e ra n d“ i nv i t r o ”i nh u m a nl u n g - t u m o rA 5 4 9c e l l s
and keratinocytes NCTC 2544. These cell lines were chosen,
having previously been shown to lack, respectively, PPARα
expression and PPARγ expression.
From our observations, it appears that PPARγ is cor-
related with an inhibition of cell proliferation that is notG. Martinasso et al. 5
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Figure 3: Cell growth, and PPARγ,P P A R β, and c-Myc protein contents, in human lung tumor A549 cells treated with DHA. (a) Cell growth:
24hoursafterseeding,cellsweretreatedwith50μMofDHAforafurther48hours.Controlcellsweretreatedwithvehiclealone.Thenumber
of cells/cm2 counted in the monolayer is represented as mean ± SD of 3 experiments. (b) Protein content of PPARγ,P P A R β, and (c) c-Myc:
protein content was determined by Western blot analysis. The densitometry value given for each protein referred to the corresponding β-
actin value and was expressed by arbitrarily normalizing the control value to 1. Means with diﬀerent letters are signiﬁcantly diﬀerent from
one another (P<. 05) as determined by analysis of variance followed by post hoc Newman-Keuls analysis.
accompanied by any increase of apoptosis: in specimens
of colon cancer from patients undergoing surgery, the
expression of PPARγ was higher than in mucosa specimens.
Together with this increase, reduced c-Myc and PCNA
protein contents were observed, indicating lower cell pro-
liferation in tumor than in mucosa specimens. PPARγ is
overexpressed not only in colon cancer but also in other
tumor types, such as in primary human lung tumors. The
increased expression of PPARγ in these tumors versus the
corresponding normal tissue has been demonstrated both
by immunochemical staining and by Western blotting [21].
AnincreasedPPARγ expression has alsobeen reported in
lung-tumor A549 cells, when cell proliferation was reduced
by treating them with the PPAR ligand, DHA. Also in this
case, the increase was accompanied by a reduction of c-Myc
content compared to controls. At the PUFA concentrations
used, neither necrosis nor apoptosis was evidenced. In these
A549 cells treated with PUFA, the increase in PPARγ expres-
sion was paralleled by an increase in PPARβ, possibly indi-
cating that this PPAR is also important, whereas the modiﬁ-
cation of PPARα was not signiﬁcant, since it failed to occur
in this type of cell.
In previous work, we reported the involvement of PPARγ
in tumor-cell proliferation and diﬀerentiation in hepatoma
and lung tumor cells [18, 19, 22–24]. Other groups have also
determined this involvement: exposure of cultured human
colorectalcancercelllinestoPPARγ agonistsinhibitsgrowth,
associated with G1 cell cycle arrest, and it increases several6 PPAR Research
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Figure 4: Apoptosis, and PPARα,P P A R β, Bcl-2, and Bad protein contents, in human keratinocytes NCTC 2544 treated with cloﬁbrate. (a)
Apoptosis: 24 hours after seeding, cells were treated with 250μM cloﬁbrate (CLOF) for a further 48 hours. Control cells were treated with
vehicle alone. Apoptosis was determined by ﬂow cytometric analysis. The percentages of apoptotic cells are presented as means ± SD of 3
experiments. (b) and (c) Protein content of PPARα,P P A R β, Bcl-2, and Bad: protein content was determined by Western blot analysis. The
densitometry value given for each protein and for each patient referred to the corresponding β-actin value and was expressed by arbitrarily
normalizing the control value to 1. Means with diﬀerent letters are signiﬁcantly diﬀerent from one another (P<. 05) as determined by
analysis of variance followed by post hoc Newman-Keuls analysis. ∗ t test, treated cells versus untreated cells (P<. 05).
markers of diﬀerentiation [25, 26]. Moreover, resveratrol has
also been found to inhibit cell growth of both Caco-2 and
HCT-116 cells in a dose- and time-dependent manners, in-
ducing PPARγ and p38 MAPK [27]. Similarly, treatment of
lung adenocarcinoma cells (A549) with troglitazone inhibits
cell growth in a dose-dependent manner, due to inhibited
cell proliferation [28]. The cell cycle proﬁle reveals an ar-
rest at G0-G1 with a concomitant downregulation of G0-
G1 cyclins D and E. Similar to troglitazone, nonsteroidal
anti-inﬂammatorydrugs(NSAIDs)mediatecyclooxygenase-
independent inhibition of lung cancer cell growth through
PPARγ activation [29].
Unlike our work, others have found that PPARγ activa-
tion not only inhibits lung-cancer cell growth, increases cell
diﬀerentiation, and induces cell-cycle arrest, but that it also
induces apoptosis [30].
With regard to PPARα, the results reported here show
that changes in the expression of this transcription factor
are probably involved in modulating apoptosis. Determi-
nation of PPARα “in vivo” in specimens of colon cancer
showed it to be decreased in comparison with mucosa spec-
imens, alongside an increase in the antiapoptotic proteins
Bcl-2 and Bcl-XL. It can be conﬁrmed that the PPARα de-
crease and the antiapoptotic-protein increase are involved in
reducingapoptosisbydeterminingcellsinapoptosisthrough
TUNEL staining; this showed fewer stained nuclei in cancer
specimens than in the corresponding mucosa. Other authors
havealsoreportedasigniﬁcantdecreaseinPPARαexpression
in human tubular adenomas compared to normal human
colonic epithelial cells, and this observation has raised inter-
est in investigating PPARα as a therapeutic target to prevent
adenoma formation [31]. PPARα and PPARγ ligands haveG. Martinasso et al. 7
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Figure 5: Apoptosis in human keratinocytes NCTC 2544 treated
with cloﬁbrate. Twenty four hours after seeding, cells were treated
with 250μMc l o ﬁ b r a t ef o raf u r t h e r4 8 h r s .C o n t r o lc e l l sw e r e
treated with vehicle alone. Apoptosis was determined by TUNEL
staining. Panel A, control cells; Panel B, cells treated with cloﬁbrate.
also been shown to play a potential role in suppressing both
hyperlipidemia and polyp formation in Apc gene-deﬁcient
mice, an animal model for human familial adenomatous
polyposis [28].
To strengthen the hypothesis of the involvement of
PPARα in apoptosis, tests were run on keratinocytes NCTC
2544, since they lack PPARγ. The speciﬁc PPARα ligand,
cloﬁbrate, induced apoptosis in these cells, the eﬀect being
accompanied by PPARα induction and modulation of apop-
totic proteins.
In the tumor cell line SK-HEP-1 treated with PPARα lig-
ands, such as CLA or Wy-14643, apoptosis was also induced
accompanied by PPARα induction, Bcl-2 decrease, and Bad
i n c r e a s e( s e e[ 18] and other data submitted for publication).
Fibrates have also been demonstrated to induce apoptosis in
glioblastoma cell lines [32] and in other hepatoma cells [33].
On the contrary, other studies have shown that activa-
tion of PPARα with Wy-14643 inhibited proliferation and
migration of smooth muscle cells (SMCs) rather than induc-
ing apoptosis. These results are supported by the ﬁnding that
the PPARα ligand cloﬁbrate, which is used clinically to re-
duce serum triglyceride levels, as well as the ligand GW7647,
prevented DNA synthesis by SMCs [34].
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Figure 6: Cell growth and apoptosis, respectively, in A549 and
NCTC 2544 cells after treatment with antagonist and ligand of
PPARs. (a) Cell growth in A549 cells: 24 hours after seeding, cells
were treated with 50μM of DHA and/or 10μM GW9662 for a fur-
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24 hours after seeding, cells were treated with 250μMc l o ﬁ b r a t e
(CLOF) and/or 5μMM K 8 8 6f o raf u r t h e r4 8h o u r s .C o n t r o lc e l l s
were treated with vehicle alone. Apoptosis was determined by ﬂow
cytometricanalysis.Thepercentagesofapoptoticcellsarepresented
as means ± SD of 3 experiments. Means with diﬀerent letters are
signiﬁcantly diﬀerent from one another (P<. 05) as determined by
analysis of variance followed by post hoc Newman-Keuls analysis.
Unlike our results, others have reported that rodents de-
velop tumors in response to exposure to a wide range of
PPARα ligands, suggesting that the causal events are activa-
tion of PPARα, increase of cell proliferation, and inhibition
of apoptosis. However, the same study found that human
cells are not susceptible to these eﬀects [35, 36].
The induction of apoptosis in NCTC 2544 cells was ac-
companied, alongside the increased expression of PPARα,
also by decreased PPARβ expression. These results are in
agreementwiththeﬁndingthatPPARβisinvolvedincellsur-
vival [37].8 PPAR Research
TheinvolvementofPPARγespeciallyincellproliferation,
and of PPARα especially in apoptosis, was demonstrated by
using speciﬁc antagonists, which had the eﬀect, respectively,
of preventing inhibition of cell proliferation by DHA, and of
preventing induction of apoptosis by cloﬁbrate.
The reason for the diﬀerent eﬀects of PPAR ligands, that
is, decrease of cell proliferation in some tumor cells inducing
PPARγ, or induction of apoptosis in others inducing PPARα,
is not yet clear. Moreover, the results obtained on treating
cell lines with PPAR ligands conﬁrm observations in colon
cancer: there is an inverse correlation between PPARα and
Bcl-2 and between PPARγ and c-Myc.
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